The team

Executive Committee

Guy-Charles Fanneau de La Horie

Guy-Charles Fanneau de La Horie, CEO
Dr Fanneau de La Horie has over 20 years of experience in the pharmaceutical and biotechnology industries. Before joining Pherecydes Pharma, he held a number of international management roles, including posts at Schering-Plough, Biogen and IDM, in both Europe and the US.

More recently, he was managing director of PathoQuest, a company developing a NGS-based infectious disease diagnostic technology. Between 2006 and 2013 he was the CEO of Neovacs and coordinated the 2010 IPO.

Prior to that, he spent eight years with Biogen, where he set up and ran the subsidiaries in France and Benelux. During his time with Biogen he managed the $700M salesforce in the US and held Europe-wide responsibilities for marketing, regulatory and medical affairs. A graduate of the National Veterinary School in Lyon, France (1982), Dr Fanneau de La Horie also holds an MBA from INSEAD, awarded in 1988.

Jérôme Gabard

Jérôme Gabard, COO
Starting at the bench in DuPont de Nemours plant biotechnology research facility (Wilmington, DE, USA) in the late eighties, Jérôme has been since developing professional skills in marketing and business development.

Prior to join Pherecydes Pharma he was Life Sciences Director at The Marketech Group, to develop company sales and to perform strategic and operational market research studies for start up’s or big pharma.

He is experienced in managing private innovative R&D start up’s (Euroclide) and to build value through merger-acquisition (Faust Pharmaceuticals, today Domain Therapeutics).
During his career he has been involved in a variety of R&D industrial projects, related to plant biotechnology, crop protection, food pathogen diagnostics, information management and drug discovery.


Patrick Champion-Arnaud

Patrick Champion-Arnaud, CMO
Patrick is an expert in biologicals manufacturing. Before joining Pherecydes, he was Scouting Manager at Valneva in Nantes, a Biotechnology Co. involved in vaccine development. Patrick has been working on flu, pox, herpes, lenti, adeno… viruses to name a few.

His knowledge in virology coupled to vaccine manufacturing process development is a good combination to develop pharmaceutical bacteriophage drugs.
Patrick worked also at the Harvard Medical School (Boston, MA, USA) after getting his PhD in molecular virology from Nantes University (France).

Cindy Fevre

Cindy Fevre, CSO
Cindy is a microbiologist, expert in bacteriology. She got her PhD from Pierre & Marie Curie University at the Pasteur Institute (Paris, France). She studied antibiotic resistance, virulence and genetic diversity of Klebsiella genus. Afterwards, she worked on other major clinical pathogens such as Listeria and Staphylococcus aureus.

Before joining Phercydes Pharma, Cindy also developped a new Phage Display method and acquired a deep knowledge in bacteriophage biology and genomics.

Through an international experience (UMC Utrecht, Netherlands) she managed research collaboration with industrial potential and led a team of pluridisciplinar and multicultural researchers.

Laure Saujet

Laure Saujet, Directrice de Recherche par intérim
Laure joined the Pherecydes team in december 2017. She is currently replacing Cindy Fevre, CSO, during her maternity leave at Pherecydes Pharma.

She has a PhD on microbiology obtained in 2013 at Pasteur Institute. She published 10 scientific articles including 3 in first author.

After her thesis, she worked on hydrogenases at the CEA of Saclay for one year, leading to 3 publications. Then, she worked as synthetic biology project manager on bacteriophages at Eligo Bioscience for 2 years.

As first employee of this start up, she was responsible of the development of phagemids specifically targeting adherent invasive E. coli implicated in Crohn's disease.

Pherecydes brings together a multidisciplinary team of PhD, veterinarian, engineers, assistant engineers and technicians.